In the first sensitivity analysis, after excluding patients who had ever previously used PDE5 inhibitors, we examined the association between post-diagnostic use of alprostadil and the risk of metastasis and CRC-specific mortality. This evidence concerns the gene PDE5A and colorectal carcinoma.